Comparison of efficacy and safety of empagliflozin vs linagliptin added to premixed insulin in patients with uncontrolled type 2 diabetes: A randomized, open-label study

恩帕吉菲 利格列汀 医学 2型糖尿病 胰岛素 内科学 糖尿病 2型糖尿病 随机对照试验 血压 胃肠病学 二肽基肽酶-4抑制剂 糖尿 内分泌学 泌尿科
作者
S.-C. Liu,C.-C. Lee,Shu‐Lin Chuang,Fang‐Ju Sun,Yi Zhang
出处
期刊:Diabetes & Metabolism [Elsevier BV]
卷期号:47 (3): 101184-101184 被引量:4
标识
DOI:10.1016/j.diabet.2020.08.001
摘要

Sodium-glucose cotransporter-2 (SGLT2) inhibitors and dipeptidyl peptidase (DPP)-4 inhibitors added to insulin regimens in patients with type 2 diabetes mellitus (T2DM) can improve glycaemic control. This study compared the efficacy and safety of empagliflozin and linagliptin added to premixed insulin therapy in patients with poorly controlled T2DM.In this 24-week, open-label, parallel-design randomized controlled trial, patients with poorly controlled T2DM despite a premixed insulin regimen were randomized to receive 5mg of linagliptin (n=53) or 25mg of empagliflozin (n=53) for 24 weeks.At week 24, changes in glycated haemoglobin (HbA1c) from baseline were -0.06±0.17% and -1.01±0.16% in the linagliptin and empagliflozin groups, respectively, and the mean treatment HbA1c difference was -0.88% (95% CI: -1.33, -0.43). At week 24, the empagliflozin group showed significant reductions, compared with the linagliptin group, in fasting plasma glucose (P<0.001), body weight (P<0.001), systolic blood pressure (P=0.003) and total daily insulin dose (P=0.042). Hypoglycaemia was reported to be slightly, and not significantly, higher in the empagliflozin group vs linagliptin group (30.2% vs 22.6%, respectively; P=0.51). Similar percentages of patients (1.9%) had urinary tract infections in the two groups.In Asian patients with inadequately controlled T2DM while taking premixed insulin, the addition of empagliflozin for 24 weeks provided better glycaemic control and greater reductions in body weight and systolic blood pressure than the addition of linagliptin. Clinical Trial Registration #: NCT03458715.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
隐形曼青应助青青子衿采纳,获得10
刚刚
今后应助潇湘雪月采纳,获得10
1秒前
NexusExplorer应助crazy采纳,获得10
1秒前
Ava应助超帅青烟采纳,获得10
1秒前
Luffa完成签到,获得积分10
2秒前
moxi摩西发布了新的文献求助10
3秒前
5秒前
追寻电脑发布了新的文献求助10
5秒前
佳佳佳发布了新的文献求助30
8秒前
脑洞疼应助袁超采纳,获得30
9秒前
潇洒的白凝完成签到,获得积分10
13秒前
123完成签到,获得积分10
14秒前
14秒前
qphys完成签到,获得积分10
15秒前
hyf发布了新的文献求助10
15秒前
mjf111完成签到,获得积分10
18秒前
19秒前
wsj发布了新的文献求助10
19秒前
烟酒不离生完成签到,获得积分10
20秒前
21秒前
Jasper应助xyj6486采纳,获得10
22秒前
22秒前
24秒前
于平川春野完成签到 ,获得积分10
24秒前
汉堡包应助我不吃胡萝卜采纳,获得10
26秒前
26秒前
英姑应助潇湘雪月采纳,获得10
26秒前
Xw发布了新的文献求助10
26秒前
27秒前
种花家的狗狗完成签到,获得积分10
27秒前
wanci应助wsj采纳,获得10
29秒前
李昕123完成签到 ,获得积分10
30秒前
超帅青烟发布了新的文献求助10
30秒前
友好的睫毛完成签到 ,获得积分10
30秒前
量子星尘发布了新的文献求助10
32秒前
木皆完成签到,获得积分10
34秒前
36秒前
ChatGPT发布了新的文献求助10
37秒前
王炎完成签到 ,获得积分10
38秒前
李健的小迷弟应助星星采纳,获得10
38秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989390
求助须知:如何正确求助?哪些是违规求助? 3531487
关于积分的说明 11254109
捐赠科研通 3270153
什么是DOI,文献DOI怎么找? 1804887
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809174